Incannex announces enhanced development strategy for IHL-42X

Incannex (IXHL) Healthcare announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea, OSA, following statistically significant outcomes across key endpoints in its completed Phase 2 program. Importantly, IHL-42X has been granted Fast Track Designation by the U.S. Food and Drug Administration, FDA, enabling more frequent interaction with the FDA as the program advances. The updated development strategy includes a Phase 2 crossover dose-optimization study, followed by a streamlined Phase 3 clinical program. This strategy is designed to optimize efficacy, strengthen the clinical data package, and potentially accelerate the pathway toward registration while maintaining strong capital efficiency.